Ranibizumab plus fufang xueshuantong capsule versus ranibizumab alone for exudative age-related macular degeneration

Autor: Jun-Jun Wang, Qinghuai Liu, Jun-Long Huang, Jia Li, Yu-Zhi Ding, Yuanlu Shuai, Hai-Tao Pan, Zizhong Hu
Rok vydání: 2020
Předmět:
medicine.medical_specialty
Medicine (General)
Prospective Clinical Research Report
Combination therapy
genetic structures
Visual Acuity
Angiogenesis Inhibitors
Pilot Projects
Traditional Chinese medicine
Biochemistry
choroidal neovascularization
combination therapy
03 medical and health sciences
Macular Degeneration
traditional Chinese medicine
0302 clinical medicine
R5-920
Ophthalmology
Ranibizumab
medicine
Humans
Prospective Studies
age-related macular degeneration
business.industry
Biochemistry (medical)
Capsule
Cell Biology
General Medicine
Exudative age-related macular degeneration
Fufang xueshuantong
eye diseases
Choroidal neovascularization
Treatment Outcome
Intravitreal Injections
030221 ophthalmology & optometry
sense organs
medicine.symptom
business
030217 neurology & neurosurgery
Tomography
Optical Coherence
medicine.drug
Drugs
Chinese Herbal
Zdroj: The Journal of International Medical Research
Journal of International Medical Research, Vol 48 (2020)
ISSN: 1473-2300
Popis: Objective To compare the efficacy of ranibizumab plus fufang xueshuantong capsule (cFXST) with the efficacy of ranibizumab alone in treatment of exudative age-related macular degeneration. Methods This prospective, randomized, controlled, pilot study included 38 eyes from 38 patients with exudative age-related macular degeneration (AMD) that were randomly allocated into two cohorts of 19 eyes each: ranibizumab (Cr) and ranibizumab plus cFXST (Cfr). All patients received three monthly injections of ranibizumab. Patients in Cfr also received daily oral supplementation of cFXST. Best corrected visual acuity (BCVA) and thickness of the choroidal neovascularization-pigment epithelial detachment (CNV-PED) complex (measured by optical coherence tomography) were recorded at baseline and at 1 and 3 months after the first intravitreal injection of ranibizumab. Results In the Cfr, the CNV-PED complex thickness was reduced by 31.7% and 36.1% at 1 and 3 months, respectively; these reductions were significantly greater than the 19.7% and 24.2% reductions in the Cr. BCVA improvement was significantly greater in the Cfr than in the Cr after 3 months; the proportion of patients with functional response was also greater in the Cfr than in the Cr (16/16 vs. 8/17). Conclusion Oral cFXST increases the efficacy of short-term ranibizumab treatment for exudative AMD.
Databáze: OpenAIRE
Externí odkaz: